Author:
Pan Irene Z.,Carey Jessica R.,Jacobs Joshua A.,Dechand John,Sessions Joshua J.,Sorensen Teshia,Penn Brittany A.,Mayeux Jennalyn D.,Hatton Nathan D.,Ryan John J.
Reference23 articles.
1. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial138390
TapsonVF
TorresF
KermeenF
KeoghAM
AllenRP
FrantzRP
10.1378/chest.11-221222628490Chest.1422012
2. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial9528
TapsonVF
JingZC
XuKF
PanL
FeldmanJ
KielyDG
10.1378/chest.12-287523669822Chest.1442013
3. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial;Jing;Circulation.,2013
4. Combination therapy with oral treprostinil for pulmonary arterial hypertension: a double-blind, placebo-controlled study;White;Am J Respir Crit Care Med,2019
5. Selexipag for the treatment of pulmonary arterial hypertension;Sitbon;N Engl J Med.,2015
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献